+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 38 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness of the drug cemiplimab as adjuvant immunotherapy for patients with stage II-IIIA non-small cell lung cancer NSCLC who have had their tumors surgically removed and who have not received prior chemotherapy. This phase III trial focuses on comparing cemiplimab treatment to observation alone, specifically in patients whose tumors show PD-L1 expression of 1% or higher. The main goal is to measure disease-free survival, which means the time patients remain free from cancer recurrence or death. Participants in the experimental group receive cemiplimab intravenously at 350 mg every 3 weeks for 4 cycles, followed by 700 mg every 6 weeks for up to 6 cycles or until cancer returns or unacceptable side effects occur. Another group is assigned to observation without additional treatment. The study treatment schedules include specific dosing intervals and duration, designed to monitor the impact of cemiplimab on preventing cancer recurrence after surgery. Throughout the trial, participants will be monitored regularly for disease recurrence and side effects. Assessments include tracking disease-free survival and overall survival for up to approximately 59 months from randomization. Safety will be evaluated by documenting adverse events from the time of informed consent until the trial ends. Participants must comply with scheduled visits and testing to help researchers collect information on treatment effects and safety over the long term.

Age: 18Years +All GendersPhase 3
35 locations
O

Actively Recruiting

Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.

Age: 18Years +All Genders
61 locations
P

Actively Recruiting

Researchers are conducting a Phase 3 randomized trial to evaluate how well azenosertib works and how safe it is compared to chemotherapy chosen by the doctor for women with platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancers that test positive for cyclin E1 protein. This cancer type relies on WEE1 for cell cycle control, and azenosertib targets this pathway to increase tumor cell damage and death. The study compares two treatment groups one receives azenosertib orally at 400 mg daily on a schedule of 5 days on and 2 days off, while the other group receives chemotherapy selected by the investigator according to protocol guidelines. The chemotherapy options include paclitaxel, gemcitabine, pegylated liposomal doxorubicin PLD, or topotecan, all given intravenously. Treatments continue as per the study plan to assess their effects. Participants will be closely monitored for up to about 24 months after the last person enrolls. Researchers will perform regular assessments including tumor measurements using RECIST criteria, quality of life questionnaires, and tracking of side effects or adverse events. The main outcome measured is progression-free survival, with additional evaluations of overall survival and response rates. Safety and quality of life changes will also be followed throughout the study.

Age: 18Years +FEMALEPhase 3
59 locations
P

Actively Recruiting

Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.

Age: 18Years +All GendersPhase 3
277 locations
E

Actively Recruiting

Researchers are evaluating the effects of the medicine imlunestrant LY3484356 on premenopausal women with early estrogen receptor-positive, HER2-negative breast cancer. The study includes two groups one to compare imlunestrant with and without ovarian suppression against tamoxifen over up to 29 days, and another to assess imlunestrants effects on the ovaries compared to tamoxifen over up to 6 months. This phase 2 trial aims to understand treatment impacts on breast cancer cells and ovarian function. Participants receive different treatments depending on their group in Cohort 1, some take imlunestrant orally alone, some take it with subcutaneous goserelin to suppress ovarian function, and others take oral tamoxifen. In Cohort 2, participants take either oral imlunestrant or oral tamoxifen without ovarian suppression. Treatments last up to 29 days for Cohort 1 and up to 6 months for Cohort 2. During the study, participants will provide tumor samples before and during treatment, and researchers will monitor tumor markers such as Ki-67, estrogen receptor, and progesterone receptor expression. They will also track ovarian cysts over 180 days. The study includes assessments of organ function and performance status, with participant involvement lasting up to 6 months depending on the cohort.

Age: 18Years +FEMALEPhase 2
90 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a chemotherapy payload, compared to treatment chosen by physicians including paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine for patients with first-line metastatic triple-negative breast cancer TNBC or low estrogen receptor ER-low, HER2-negative breast cancer who cannot receive anti-PDL1 or endocrine therapies. This study includes adults with locally advanced, recurrent inoperable, or metastatic disease who meet specific eligibility criteria. Participants are randomly assigned to receive iza-bren or one of the physicians choice chemotherapy regimens. The treatments are given at specified doses on scheduled days. The study includes two phases Phase 2 to determine the recommended dose of iza-bren and Phase 3 to compare progression-free survival and other outcomes. The study will last several years, with follow-up extending up to approximately 47 months after randomization. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests, and monitoring for adverse events. Quality of life questionnaires will also be completed. Researchers will track progression-free survival, overall survival, treatment-related side effects, tumor size changes, and patient-reported outcomes to evaluate the treatments. The total participation duration may extend up to several years depending on treatment response and follow-up requirements.

Age: 18Years +All GendersPhase 2Phase 3
295 locations
E

Actively Recruiting

Researchers are studying CRB-701, a targeted chemotherapy known as an antibody drug conjugate, to see how well it works as a treatment for oropharyngeal throat, tonsil cancer in patients who have already had platinum-based chemotherapy or immunotherapy. The study also aims to learn about the safety of CRB-701 and how it affects participants quality of life, comparing it with standard care medicines commonly used for this cancer. Participants are randomly assigned to receive either CRB-701 at a dose of 3.6 mgkg intravenously every three weeks or one of the investigators choice therapies, which include capecitabine, cetuximab, or docetaxel. They will continue treatment until the cancer is no longer measurable or controlled. Treatment schedules vary by drug but generally follow cycles of 21 days, with imaging scans like CT or MRI every six weeks to assess cancer response. During the study, participants will visit the clinic every three weeks for infusions and undergo scans every six weeks to monitor their cancer. They will also complete questionnaires to assess their health status and quality of life. Researchers will track response rates, overall survival, progression-free survival, adverse events, and treatment modifications over approximately two to three years from randomization to evaluate treatment effects and safety.

Age: 18Years +All GendersPhase 3
111 locations
T

Actively Recruiting

Researchers are evaluating a new medicine called Sofetabart Mipitecan Sofe-M in a three-part clinical trial for people with certain types of ovarian, peritoneal, and fallopian tube cancers. The study focuses on patients with platinum-resistant cancer, whose disease worsened during or within six months after platinum chemotherapy, and those with platinum-sensitive cancer, whose disease remained controlled for at least six months after platinum treatment. The trial aims to determine if Sofe-M is more effective and to better understand its safety compared to standard treatments. Participants receive different treatments depending on their group. In Part A, patients with platinum-resistant disease receive Sofetabart Mipitecan or chemotherapy or Mirvetuximab Soravtansine, all given intravenously. In Parts B and C, patients with platinum-sensitive disease receive Sofetabart Mipitecan plus Bevacizumab or platinum-based chemotherapy plus Bevacizumab, also administered intravenously. The choice of chemotherapy is made by the investigator. Treatments are given in parallel groups. During the study, participants undergo regular assessments including imaging scans to monitor disease progression, safety evaluations, and quality of life questionnaires. Researchers measure progression-free survival as the primary outcome, along with overall survival, response rates, symptom changes, and drug levels in the blood. Each participants time in the study varies based on their response to treatment, with follow-up continuing up to 70 months after randomization to track outcomes and safety.

Age: 18Years +All GendersPhase 3
264 locations
O

Actively Recruiting

Researchers are conducting a prospective observational study to describe the population affected by Epithelioid Sarcoma ES. The study aims to deepen understanding of the diseases natural history, explore differences between classical-type and proximal-type ES variants, and address outstanding questions regarding its management to help tailor treatments and improve patient outcomes. Participants diagnosed with localized or advanced epithelioid sarcoma and treated at Italian reference centers for sarcoma will be observed. Treatments for ES will follow disease guidelines, and the study will track therapies such as radiotherapy and chemotherapy over time. The study does not involve experimental treatments but focuses on collecting detailed information about patient care and disease progression. Throughout the study, researchers will monitor the types of treatments given from diagnosis up to 60 months, including regular assessments of radiotherapy and chemotherapy every six months. They will also study predictive biomarkers for treatment response at diagnosis and during disease progression when biopsies are performed. Participants will provide informed consent and are expected to comply with treatment and follow-up during the study period, which may continue until 2030.

All AgesAll Genders
11 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TORL-1-23 in women with advanced platinum-resistant epithelial ovarian cancer, including primary peritoneal and fallopian tube cancers that express Claudin 6. This Phase 2 study focuses on patients whose cancer has not responded well to platinum-based chemotherapy and aims to understand how this treatment works in this population. The study involves three groups receiving different doses of TORL-1-23 given as an intravenous infusion on Day 1 of every 21-day cycle. Alongside TORL-1-23, participants receive pegfilgrastim by subcutaneous injection on Day 4 of each cycle to support their immune system. Each treatment cycle lasts three weeks, and all participants follow this schedule throughout the study period. Participants will be monitored regularly with scans and lab tests to measure how their cancer responds to treatment, including progression-free survival and overall survival. Safety will be checked by recording side effects and laboratory abnormalities from the start of treatment until 30 days after the last dose. The study will last about 40 months, during which disease progression and other outcomes will be tracked at set intervals to assess the treatments effects.

Age: 18Years +FEMALEPhase 2
66 locations

1-10 of 38

1